pyrroles has been researched along with imrecoxib in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, AP; Bai, JY; Chen, XH; Cheng, GF; Guo, ZR; Shen, F | 1 |
| Dong, Y; Huang, HH; Li, Q; Zhong, DF | 1 |
| Chu, FM; Guo, ZR; Sun, J; Xie, ZY; Xu, HY; Zhang, P; Zhong, DF | 1 |
| Chu, FM; Gong, AS; Guo, ZR; Sun, YM; Xu, HY; Zhang, P; Zhong, DF | 1 |
| Chu, F; Guo, Z; Sun, Y; Xu, H; Zhang, H; Zhang, P; Zhang, Y; Zhong, D | 1 |
| Chu, F; Feng, Z; Guo, Z; Sun, P | 1 |
| Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF | 1 |
| Gao, GM; Jiang, DB; Kan, QC; Li, YM; Liu, SY; Xu, PH; Zhang, LL; Zheng, XL; Zheng, ZH | 1 |
| Chen, X; Hou, X; Yu, S; Zhang, Y; Zhong, D; Zhou, J; Zhou, L | 1 |
| Chen, XY; Gong, Y; Hou, XY; Peng, WX; Zhang, YF; Zhong, DF; Zhu, RH; Zuo, CZ | 1 |
| Chen, X; Dai, X; Hou, X; Yang, Y; Zhang, Y; Zhong, D | 1 |
| Huang, J; Li, W; Liu, WY; Pei, Q; Tan, HY; Wang, Y; Xie, JL; Yang, GP; Yang, XY; Zhang, H | 1 |
| Huang, X; Li, Z; Liu, Y; Shi, S; Yang, C; Yang, T; Zhang, R; Zhang, Y; Zhou, J | 1 |
| Pei, Q; Xie, JL; Yang, GP; Zhang, H | 1 |
| Srinivas, NR | 1 |
| Huang, J; Li, Y; Pei, Q; Tan, H; Wang, J; Wang, Y; Yang, G; Yu, J; Zhang, H | 1 |
| Guo, W; Li, J; Liu, Y | 1 |
| An, Q; Dong, J; Jin, Y; Liu, X; Wang, K; Wu, X; Zhang, Z | 1 |
| Chen, KM; Chu, YR; Tong, WQ; Wang, C; Wang, JX; Wang, XL; Xu, SQ; Zong, HX | 1 |
| Hu, C; Luo, Z; Shen, Q; Shu, S; Wang, Y; Yang, L; Zhu, X | 1 |
4 trial(s) available for pyrroles and imrecoxib
| Article | Year |
|---|---|
The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
Topics: Biomarkers; Celecoxib; Demography; Follow-Up Studies; Humans; Inflammation; Intercellular Signaling Peptides and Proteins; Pyrroles; Spondylarthritis; Sulfides; Treatment Outcome | 2017 |
Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Topics: Adult; Aged; Cyclooxygenase 2 Inhibitors; Drug Interactions; Female; Humans; Male; Middle Aged; Osteoarthritis; Pyrroles; Renal Insufficiency; Sulfides | 2019 |
Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Topics: Adolescent; Adult; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP2C9; Genotype; Humans; Male; Pharmacogenomic Testing; Pyrroles; Sulfides; Vitamin K Epoxide Reductases; Warfarin | 2019 |
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study.
Topics: Analgesia; Celecoxib; Humans; Meperidine; Pain, Postoperative; Pyrroles; Sulfides | 2022 |
16 other study(ies) available for pyrroles and imrecoxib
| Article | Year |
|---|---|
Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Prostaglandin-Endoperoxide Synthases; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Sulfides; U937 Cells | 2004 |
[Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs].
Topics: Aryl Hydrocarbon Hydroxylases; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Hydroxylation; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sulfides | 2005 |
Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib.
Topics: Animals; Biotransformation; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Male; Microsomes, Liver; Pyrroles; Quinine; Rats; Rats, Wistar; Sulfides | 2006 |
Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes.
Topics: Animals; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Ketoconazole; Male; Microsomes, Liver; NADP; Pyrroles; Rats; Rats, Wistar; Sulfides | 2006 |
Metabolism and excretion of imrecoxib in rat.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Injections, Intravenous; Oxidation-Reduction; Pyrroles; Rats; Rats, Wistar; Sulfides | 2006 |
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Edema; Humans; Mice; Pyrazoles; Pyrroles; Rats; Sulfides; Sulfonamides | 2009 |
[Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclobutanes; Cytoskeletal Proteins; Heterografts; Humans; Lung Neoplasms; Lymph Nodes; Male; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Pyrroles; Random Allocation; RNA, Messenger; Sulfides; Transplantation, Heterologous; Tumor Burden | 2016 |
Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate.
Topics: Administration, Oral; Aldehydes; Animals; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP3A; Humans; Male; Microsomes, Liver; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfides | 2018 |
Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
Topics: Administration, Oral; Adult; Antifungal Agents; Area Under Curve; China; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Drug Interactions; Fluconazole; Healthy Volunteers; Humans; Male; Pyrroles; Random Allocation; Sulfides; Young Adult | 2018 |
Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Humans; Limit of Detection; Linear Models; Liver Diseases; Pyrroles; Reproducibility of Results; Sulfides; Tandem Mass Spectrometry | 2019 |
Response by Pei et al. to letters regarding article, "Pharmacokinetic study of imrecoxib in patients with renal insufficiency".
Topics: Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients.
Topics: Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Pyrroles; Renal Insufficiency; Sulfides | 2020 |
Inhibition of imrecoxib on mRNA and protein expression of CYP2C11 enzyme in rats.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P450 Family 2; Microsomes, Liver; Pyrroles; Rats; RNA, Messenger; Steroid 16-alpha-Hydroxylase; Sulfides | 2022 |
A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
Topics: Axial Spondyloarthritis; Celecoxib; Humans; Pyrroles; Sulfides; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2022 |
Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Healthy Volunteers; Humans; Middle Aged; Pyrroles; Sulfides | 2022 |